ONE-WAYOngoing theme · still written in the latest filings

Strategic partnerships and licensing in the iPS cell and regenerative medicine businesses

A theme focused on expanding the iPS cell and regenerative medicine businesses, based on making a US company a subsidiary, establishing a domestic entity, and leveraging synergies with J-TEC. This has progressed to granting BlueRock development and commercialization licenses and recognizing license revenue.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2016 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat